In Brief: FDA reform
FDA reform: Senate Labor Committee Chairman Jeffords (R-Vt.) reiterates request for Administration's legislative proposals, stating in an April 18 letter to HHS Secretary Shalala that "I am deeply concerned that we will be forced to act [on PDUFA reauthorization and FDA reform] without the input of the FDA." Jeffords' office indicates that the agency did not meet the senator's April 25 deadline for submission of a proposal. FDA did participate in a staff-level meeting on April 25 at the committee's request and is said to be in the process of developing legislative language. Jeffords writes that he intends to have legislation linking PDUFA and FDA "improvements" ready for May committee mark-up...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth